0.00Open1.60Pre Close0 Volume23 Open Interest2.00Strike Price0.00Turnover342.36%IV-1.64%PremiumAug 16, 2024Expiry Date1.66Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8720Delta0.0623Gamma2.29Leverage Ratio-0.0140Theta0.0008Rho1.99Eff Leverage0.0021Vega
VistaGen Therapeutics Stock Discussion
Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine
VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M
Jun. 11, 2024 4:23 PM ETVistagen Therapeutics, Inc. (VTGN) StockBy: Mary Christine Joy, SA News Editor
VistaGen Therapeutics press release (NASDAQ:VTGN): Q4 GAAP EPS of -$1.52 misses by $1.16.
Revenue of $1.06M (vs. -$0.23M last year) beats by $0.86M.
Shares +0.8%.
Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder...
Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
238k shares bought 5.4
No comment yet